BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 20212230)

  • 21. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
    Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
    JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paraneoplastic neurologic syndromes: approaches to diagnosis and treatment.
    Bataller L; Dalmau J
    Semin Neurol; 2003 Jun; 23(2):215-24. PubMed ID: 12894387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Lung cancer and paraneoplastic syndromes].
    Jurado Gámez B; García de Lucas MD; Gudín Rodríguez M
    An Med Interna; 2001 Aug; 18(8):440-6. PubMed ID: 11589085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.
    Raspotnig M; Vedeler C; Storstein A
    J Neurol Sci; 2015 Jan; 348(1-2):41-5. PubMed ID: 25467140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of paraneoplastic neurological syndromes: report of an EFNS Task Force.
    Vedeler CA; Antoine JC; Giometto B; Graus F; Grisold W; Hart IK; Honnorat J; Sillevis Smitt PA; Verschuuren JJ; Voltz R;
    Eur J Neurol; 2006 Jul; 13(7):682-90. PubMed ID: 16834698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Paraneoplastic neurological syndromes].
    Storstein A; Vedeler CA
    Tidsskr Nor Laegeforen; 2009 Mar; 129(6):524-8. PubMed ID: 19282889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on paraneoplastic and autoimmune disorders of the central nervous system.
    Rosenfeld MR; Dalmau J
    Semin Neurol; 2010 Jul; 30(3):320-31. PubMed ID: 20577938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Classic paraneoplastic syndromes: diagnostic and treatment approach].
    Gállego Pérez-Larraya J; Dalmau J
    Neurologia; 2008 Sep; 23(7):441-8. PubMed ID: 18726722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects.
    Storstein A; Vedeler CA
    Adv Clin Chem; 2007; 44():143-85. PubMed ID: 17682342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome.
    Honnorat J
    Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):127-9. PubMed ID: 25546790
    [No Abstract]   [Full Text] [Related]  

  • 31. Onconeural antibodies are essential to diagnose paraneoplastic neurological syndromes.
    Honnorat J
    Acta Neurol Scand Suppl; 2006; 183():64-8. PubMed ID: 16637934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrathecal synthesis of onconeural antibodies in patients with paraneoplastic syndromes.
    Corsini E; Gaviani P; Chiapparini L; Lazzaroni M; Ciusani E; Bisogno R; Silvani A; Salmaggi A; Bernardi G
    J Neuroimmunol; 2016 Jan; 290():119-22. PubMed ID: 26711581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical approach to diagnosis of paraneoplastic neurologic syndromes.
    Graus F
    Handb Clin Neurol; 2024; 200():79-96. PubMed ID: 38494298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [An autopsied case of paraneoplastic neurologic syndrome (limbic encephalitis, cerebellar degeneration, and pseudohypertrophy in the inferior olivary nuclei) associated with T cell lymphoma].
    Ishihara K; Suzuki Y; Shiota J; Kawamura M; Nakano I
    Rinsho Shinkeigaku; 2005 Aug; 45(8):583-9. PubMed ID: 16180707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paraneoplastic syndromes in patients with nasopharyngeal cancer.
    Toro C; Rinaldo A; Silver CE; Politi M; Ferlito A
    Auris Nasus Larynx; 2009 Oct; 36(5):513-20. PubMed ID: 19111998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Paraneoplastic cerebral syndromes with oto-neuro-ophthalomologic manifestations].
    Dalmau J; Porta-Etessam J
    Rev Neurol; 2000 Dec 16-31; 31(12):1213-9. PubMed ID: 11205562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Updates in the Management of Paraneoplastic Syndrome.
    Verma N; Jaffer MH; Kolli AS; Mokhtari S
    Semin Neurol; 2024 Feb; 44(1):36-46. PubMed ID: 38183975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical analysis of anti-Ma2-associated encephalitis.
    Dalmau J; Graus F; Villarejo A; Posner JB; Blumenthal D; Thiessen B; Saiz A; Meneses P; Rosenfeld MR
    Brain; 2004 Aug; 127(Pt 8):1831-44. PubMed ID: 15215214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Update on neurological paraneoplastic syndromes.
    Höftberger R; Rosenfeld MR; Dalmau J
    Curr Opin Oncol; 2015 Nov; 27(6):489-95. PubMed ID: 26335665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autonomic paraneoplastic neurological syndromes.
    Lorusso L; Hart IK; Ferrari D; Ngonga GK; Gasparetto C; Ricevuti G
    Autoimmun Rev; 2007 Jan; 6(3):162-8. PubMed ID: 17289552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.